"Wooden Sister" Cathy Wood's ARK investment management company disclosed its trading records for October 15th, continuing to increase its holdings in artificial intelligence infrastructure and biotechnology companies, while reducing its position in some large tech stocks.
Among them, ARK purchased approximately $18.96 million of Iambic Therapeutics shares, $15.82 million of Recursion Pharmaceuticals shares, and $12.67 million of CoreWeave shares; on the other hand, it sold approximately $7.64 million of Amazon shares and reduced its holdings in companies such as Shopify and Palantir.
Main purchases: Increase positions in biotechnology and AI infrastructure.
Among them, Iambic represents the largest single purchase on that day, and the related transaction was completed through the ARKG fund. The purchase of Recursion was mainly executed through the ARKK fund.
It is worth noting that after purchasing CoreWeave on the previous trading day, ARK increased its holdings by another 192,600 shares, continuing its investment in AI, a company specializing in computing power infrastructure.
Main sales: Reduced holdings in Amazon, Shopify, and Palantir
Amazon was the target with the largest amount of reduction in holdings on that day under ARK, involving multiple ETF under its umbrella, continuing the recent selling activities.
Overall, on that day, ARK focused its trading on increasing holdings in innovative pharmaceuticals and biotechnology companies, as well as AI companies related to computing power, while reducing positions in some large technology, software, and fintech enterprises.
